Trulieve Cannabis and Cronos Group Outperform the Market in 2026
In 2026, Trulieve Cannabis (NYSE: TRLV) and Cronos Group (NASDAQ: CRON) have outperformed the S&P 500 by roughly 15 percentage points. Both stocks are up about 27% year-to-date through September 18 compared to a 12% gain for the broader market index. Trulieve has benefited from its transformation following federal rescheduling of medical marijuana and listing on the NYSE in June, which improved liquidity and investor appeal. The company reported Q2 revenue of $271 million with strong cash flow generation including $98 million in adjusted EBITDA and $74 million in free cash flow. Cronos Group is also showing robust growth driven by international expansion across Canada, Israel, and Germany. Its second-quarter net revenue surged 58% year-over-year to a record $53 million with gross margin expanding from 43% to 54%. Cronos ended June with over $827 million in cash and has been repurchasing shares as part of its capital return strategy.
Topics: cannabis industry Cronos Group S&P 500 performance Trulieve Cannabis